Immunotherapy and Liver Transplantation: A Narrative Review of Basic and Clinical Data
Immune checkpoint inhibitors (ICIs) have improved the management of patients with intermediate- and advanced-stage HCC, even making some of them potential candidates for liver transplantation. However, acute rejection has been observed after ICI therapy, challenging its safety in transplant settings...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-09-01
|
| Series: | Cancers |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2072-6694/15/18/4574 |
| _version_ | 1797580902930317312 |
|---|---|
| author | Charles-Henri Wassmer Sofia El Hajji Xenofon Papazarkadas Philippe Compagnon Parissa Tabrizian Stéphanie Lacotte Christian Toso |
| author_facet | Charles-Henri Wassmer Sofia El Hajji Xenofon Papazarkadas Philippe Compagnon Parissa Tabrizian Stéphanie Lacotte Christian Toso |
| author_sort | Charles-Henri Wassmer |
| collection | DOAJ |
| description | Immune checkpoint inhibitors (ICIs) have improved the management of patients with intermediate- and advanced-stage HCC, even making some of them potential candidates for liver transplantation. However, acute rejection has been observed after ICI therapy, challenging its safety in transplant settings. We summarize the key basic impact of immune checkpoints on HCC and liver transplantation. We analyze the available case reports and case series on the use of ICI therapy prior to and after liver transplantation. A three-month washout period is desirable between ICI therapy and liver transplantation to reduce the risk of acute rejection. Whenever possible, ICIs should be avoided after liver transplantation, and especially so early after a transplant. Globally, more robust prospective data in the field are required. |
| first_indexed | 2024-03-10T22:57:41Z |
| format | Article |
| id | doaj.art-d27aa47bd8d14d208b2b7e8134649736 |
| institution | Directory Open Access Journal |
| issn | 2072-6694 |
| language | English |
| last_indexed | 2024-03-10T22:57:41Z |
| publishDate | 2023-09-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cancers |
| spelling | doaj.art-d27aa47bd8d14d208b2b7e81346497362023-11-19T09:55:42ZengMDPI AGCancers2072-66942023-09-011518457410.3390/cancers15184574Immunotherapy and Liver Transplantation: A Narrative Review of Basic and Clinical DataCharles-Henri Wassmer0Sofia El Hajji1Xenofon Papazarkadas2Philippe Compagnon3Parissa Tabrizian4Stéphanie Lacotte5Christian Toso6Division of Abdominal Surgery, Department of Surgery, Faculty of Medicine, Geneva University Hospitals, 1205 Geneva, SwitzerlandDivision of Abdominal Surgery, Department of Surgery, Faculty of Medicine, Geneva University Hospitals, 1205 Geneva, SwitzerlandDivision of Abdominal Surgery, Department of Surgery, Faculty of Medicine, Geneva University Hospitals, 1205 Geneva, SwitzerlandDivision of Transplantation, Department of Surgery, Faculty of Medicine, Geneva University Hospitals, 1205 Geneva, SwitzerlandMount Sinai Liver Cancer Program, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10019, USADivision of Abdominal Surgery, Department of Surgery, Faculty of Medicine, Geneva University Hospitals, 1205 Geneva, SwitzerlandDivision of Abdominal Surgery, Department of Surgery, Faculty of Medicine, Geneva University Hospitals, 1205 Geneva, SwitzerlandImmune checkpoint inhibitors (ICIs) have improved the management of patients with intermediate- and advanced-stage HCC, even making some of them potential candidates for liver transplantation. However, acute rejection has been observed after ICI therapy, challenging its safety in transplant settings. We summarize the key basic impact of immune checkpoints on HCC and liver transplantation. We analyze the available case reports and case series on the use of ICI therapy prior to and after liver transplantation. A three-month washout period is desirable between ICI therapy and liver transplantation to reduce the risk of acute rejection. Whenever possible, ICIs should be avoided after liver transplantation, and especially so early after a transplant. Globally, more robust prospective data in the field are required.https://www.mdpi.com/2072-6694/15/18/4574immune checkpoint inhibitorshepatocellular carcinomaliver transplantationacute rejection |
| spellingShingle | Charles-Henri Wassmer Sofia El Hajji Xenofon Papazarkadas Philippe Compagnon Parissa Tabrizian Stéphanie Lacotte Christian Toso Immunotherapy and Liver Transplantation: A Narrative Review of Basic and Clinical Data Cancers immune checkpoint inhibitors hepatocellular carcinoma liver transplantation acute rejection |
| title | Immunotherapy and Liver Transplantation: A Narrative Review of Basic and Clinical Data |
| title_full | Immunotherapy and Liver Transplantation: A Narrative Review of Basic and Clinical Data |
| title_fullStr | Immunotherapy and Liver Transplantation: A Narrative Review of Basic and Clinical Data |
| title_full_unstemmed | Immunotherapy and Liver Transplantation: A Narrative Review of Basic and Clinical Data |
| title_short | Immunotherapy and Liver Transplantation: A Narrative Review of Basic and Clinical Data |
| title_sort | immunotherapy and liver transplantation a narrative review of basic and clinical data |
| topic | immune checkpoint inhibitors hepatocellular carcinoma liver transplantation acute rejection |
| url | https://www.mdpi.com/2072-6694/15/18/4574 |
| work_keys_str_mv | AT charleshenriwassmer immunotherapyandlivertransplantationanarrativereviewofbasicandclinicaldata AT sofiaelhajji immunotherapyandlivertransplantationanarrativereviewofbasicandclinicaldata AT xenofonpapazarkadas immunotherapyandlivertransplantationanarrativereviewofbasicandclinicaldata AT philippecompagnon immunotherapyandlivertransplantationanarrativereviewofbasicandclinicaldata AT parissatabrizian immunotherapyandlivertransplantationanarrativereviewofbasicandclinicaldata AT stephanielacotte immunotherapyandlivertransplantationanarrativereviewofbasicandclinicaldata AT christiantoso immunotherapyandlivertransplantationanarrativereviewofbasicandclinicaldata |